Sorafenib With Cirrhosis: — Why Child-Pugh Status Decides Eligibility

B7 is the lowest point in the Child-Pugh B range, and it is where some oncologists consider sorafenib on a case-by-case basis — though international guidelines do not list it as a standard recommendation for Child-Pugh B. Whether it is appropriate for you depends on your overall fitness, the stage of your cancer, and your oncologist's individual assessment of your risk. Ask directly whether sorafenib is being recommended, and whether a dose adjustment alongside close monitoring is being considered.

Your oncologist or hepatologist calculates it from five measurements: your bilirubin level, your albumin level, your prothrombin time (how quickly your blood clots), the presence and severity of ascites (fluid in the abdomen), and whether you have had episodes of hepatic encephalopathy (liver-related confusion). Each factor is given a score, and the five are added together. A total of five to six gives Child-Pugh A, seven to nine gives B, and ten or above gives C.

Most other systemic treatments for liver cancer were also studied primarily in Child-Pugh A patients, so the evidence landscape is similar across the drug class. For Child-Pugh B and C, the conversation typically shifts toward which options remain realistic given your liver function, alongside active management of cirrhosis complications and symptom control. Palliative care alongside oncology is an important part of this — it is an active treatment, not a withdrawal from care. Ask your oncologist to outline the options that apply specifically to your score and stage.

In some cases, yes. If active viral hepatitis is driving ongoing liver damage, suppressing or clearing the virus can slow further damage and, in some patients, allow partial recovery of function. This will not reverse established scarring, but it may be enough to move someone from a higher score to a lower one over time. Whether this applies to you depends on the underlying cause of your cirrhosis, so ask your team whether the cause is treatable and what a realistic benefit might look like.

Sorafenib can cause liver-related side effects, and your team will monitor your liver function through regular blood tests throughout treatment. In Child-Pugh A patients, this risk is generally considered acceptable against the potential benefit. In patients with Child-Pugh B or C, the liver has less reserve to absorb any additional stress, which is a key reason eligibility thresholds exist. If you are prescribed sorafenib, your team will tell you which results or symptoms should prompt you to call before your next scheduled appointment.

Sorafenib, where recommended by your oncologist, can be part of treatment administered through CION's day care oncology service. Response-assessment scans such as PET-CT are coordinated with partner imaging centres. CION does not provide CAR-T or cell therapy. If you have been told sorafenib is appropriate for you, ask your CION team about the practicalities of starting.